Masimo (NASDAQ:MASI) Updates FY 2025 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 5.620-5.790 for the period, compared to the consensus estimate of 5.320. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Masimo Stock Up 2.8%

Shares of NASDAQ:MASI traded up $4.05 during trading on Tuesday, hitting $149.01. The company’s stock had a trading volume of 1,439,977 shares, compared to its average volume of 639,871. Masimo has a fifty-two week low of $133.70 and a fifty-two week high of $194.88. The business has a 50 day moving average price of $144.80 and a two-hundred day moving average price of $154.07. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. The company has a market capitalization of $8.09 billion, a PE ratio of -17.49 and a beta of 1.28.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.The business had revenue of $617.00 million for the quarter. As a group, research analysts expect that Masimo will post 4.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on MASI. Weiss Ratings reissued a “sell (d)” rating on shares of Masimo in a research report on Wednesday, October 8th. BTIG Research reissued a “buy” rating and issued a $198.00 price objective on shares of Masimo in a research report on Thursday, September 11th. Zacks Research lowered shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Wall Street Zen upgraded shares of Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Finally, Piper Sandler increased their price objective on Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 6th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Masimo currently has a consensus rating of “Moderate Buy” and an average target price of $194.60.

Insider Activity

In other Masimo news, Director William R. Jellison bought 3,000 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were acquired at an average cost of $145.98 per share, with a total value of $437,940.00. Following the acquisition, the director directly owned 4,790 shares of the company’s stock, valued at $699,244.20. The trade was a 167.60% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MASI. State Street Corp raised its holdings in shares of Masimo by 0.7% in the second quarter. State Street Corp now owns 1,486,394 shares of the medical equipment provider’s stock valued at $250,041,000 after buying an additional 10,403 shares during the last quarter. Durable Capital Partners LP raised its stake in Masimo by 3.4% during the 2nd quarter. Durable Capital Partners LP now owns 1,163,898 shares of the medical equipment provider’s stock valued at $195,791,000 after acquiring an additional 38,279 shares during the last quarter. Viking Global Investors LP purchased a new stake in Masimo during the 2nd quarter valued at approximately $129,096,000. Ameriprise Financial Inc. lifted its position in Masimo by 86.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 394,487 shares of the medical equipment provider’s stock worth $66,361,000 after acquiring an additional 182,701 shares during the period. Finally, Bamco Inc. NY grew its stake in shares of Masimo by 21.2% in the 2nd quarter. Bamco Inc. NY now owns 384,589 shares of the medical equipment provider’s stock valued at $64,696,000 after purchasing an additional 67,307 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.